Beta-Glucan Composition for Reducing Age-Related Systemic Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need to prevent or reduce systemic chronic inflammation (SCI) and slow biological aging, as it contributes to various age-related chronic diseases and conditions such as type 2 diabetes, cardiovascular disease, chronic kidney disease, cancer, depression, neurodegenerative diseases, and osteoporosis.

Innovation Solution

Administering an effective amount of a composition containing beta-glucan, avenanthramides, or other phenolics to reduce the expression levels of biomarkers associated with systemic chronic inflammation, using a method that includes encapsulating the composition in a biodegradable capsule or incorporating it into foodstuff or beverages for oral consumption.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If no intervention is provided for systemic chronic inflammation, then the natural aging process progresses with increasing inflammation levels, but administering anti-inflammatory compositions may have unwanted side effects or insufficient efficacy

Engineering Contradiction:

Improveefficacy in reducing systemic chronic inflammationVSAvoidside effects from anti-inflammatory treatments

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical parameters of the treatment by using specific compounds (beta-glucan, avenanthramides, and other phenolics) with defined molecular structures and concentrations. These parameter changes enable selective anti-inflammatory action through specific biological pathways while avoiding the broad suppression effects of traditional anti-inflammatory drugs, thereby reducing side effects while maintaining efficacy.

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If traditional anti-inflammatory drugs are administered to reduce inflammation markers, then inflammation levels decrease, but they may also suppress beneficial immune responses and cause adverse effects

Engineering Contradiction:

Improveinflammation marker levelsVSAvoidsuppression of beneficial immune responses

Core Design Contradiction:

Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The patent converts potentially harmful chronic inflammation into a beneficial state by using natural compounds that selectively reduce pathological inflammation while preserving or even enhancing beneficial immune responses. The beta-glucan and avenanthramides compounds modulate the immune system to reduce harmful inflammatory markers while maintaining protective immune functions, effectively converting the harmful inflammatory state into a beneficial anti-aging effect.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If high doses of anti-inflammatory agents are used to achieve significant reduction in inflammation markers, then biomarker levels decrease more rapidly, but safety and tolerability are compromised

Engineering Contradiction:

Improverate of inflammation marker reductionVSAvoidsafety and tolerability

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by using moderate doses of multiple natural compounds (beta-glucan at 2-5g, avenanthramides at 1-2mg) that collectively achieve significant inflammation reduction without the excessive dosing required by single-agent therapies. This distributed partial action across multiple compounds provides additive or synergistic effects that achieve high productivity while maintaining safety and tolerability.

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentUS12350287B2Method of reducing age-related systemic chronic inflammation

Publication Date: 2025.07.08 QUAKER OATS CO

AI summary

A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.